Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCD | O00767 | 5/20 | 0.34 |
| ▸ | HTR1A | P08908 | 1/20 | 0.32 |
| ▸ | HTR1D | P28221 | 1/20 | 0.32 |
| ▸ | HTR1B | P28222 | 1/20 | 0.32 |
| ▸ | HTR1F | P30939 | 1/20 | 0.32 |
| ▸ | HTR2A | P28223 | 1/20 | 0.31 |
| ▸ | HTR7 | P34969 | 1/20 | 0.31 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.31 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.31 |
| ▸ | TOP2A | P11388 | 3/20 | 0.30 |
| ▸ | TOP2B | Q02880 | 3/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27268516 | 0.82 | SCD (0.47) | SCDHTR2AOPRL1 | |
| SCHEMBL16821913 | 0.82 | TOP2A (0.33) | SCDHTR1AHTR1DHTR1BHTR1F | |
| SCHEMBL16821909 | 0.82 | GLA (0.37) | SCDHTR1AHTR1DHTR1BHTR1F | |
| SCHEMBL27266648 | 0.78 | HTR2A (0.33) | SCDHTR1AHTR1DHTR1BHTR1F | |
| SCHEMBL28810629 | 0.73 | DHODH (0.32) | — | |
| SCHEMBL18280725 | 0.72 | KDM4E (0.35) | — | |
| SCHEMBL28809727 | 0.72 | DHODH (0.31) | TOP2ATOP2B | |
| SCHEMBL21624191 | 0.71 | GRM2 (0.36) | SCDHTR1AHTR1DHTR1BHTR1F | |
| SCHEMBL28810622 | 0.71 | LMNA (0.32) | OPRL1TOP2ATOP2B | |
| SCHEMBL30006217 | 0.71 | GRM2 (0.36) | SCDHTR1AHTR1DHTR1BHTR1F |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160355477-A1 | INDOLE CARBOXAMIDE DERIVATIVES AND USES THEREOF | NOVARTIS AG (CH) | 2016-12-08 | — | — | US | disclosed |
| US-9447039-B2 | Indole carboxamide derivatives and uses thereof | NOVARTIS AG (CH) | 2016-09-20 | — | — | US | disclosed |
| US-20150175539-A1 | INDOLE CARBOXAMIDE DERIVATIVES AND USES THEREOF | NOVARTIS AG (CH) | 2015-06-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150175539-A1 | INDOLE CARBOXAMIDE DERIVATIVES AND USES THEREOF | TPH1, TPH2, IARS2 | SCD 2172/4885HTR1A 48/4885HTR1D 300/4885 |
| US-20160355477-A1 | INDOLE CARBOXAMIDE DERIVATIVES AND USES THEREOF | TPH1, TPH2, IARS2 | SCD 2172/4885HTR1A 48/4885HTR1D 300/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.